Durvalumab Plus Olaparib Administered Prior to Surgery of Resectable Urothelial Bladder Cancer (NEODURVARIB)

Condition:   Urothelial Bladder Cancer Interventions:   Drug: Durvalumab;   Drug: Olaparib Sponsors:   Spanish Oncology Genito-Urinary Group;   AstraZeneca;   Sistemas Genómicos;   Apices Soluciones S.L. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials